Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine versus placebo crossover trial in children and adolescents with ADHD
ACTRN12607000535471Phase 4Not yet recruiting
- Sponsor
- Westmead Hospital
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Westmead Hospital. Primary endpoints: Inhibitory capacity and Emotional recognition. Planned start Nov 2007; status: not yet recruiting.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ACTRN12607000535471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000535471.